Saxonov Serge's Form 4 filing
10x Genomics, Inc. (TXG) · filed Nov 4, 2021
- Accession no.
- 0001567619-21-019360
- Filed
- Nov 4, 2021
- Trade date
- Nov 2, 2021
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 6 non-derivative transactions and 2 derivative transactions. Open-market sales total $2.42M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Saxonov SergeCIK 0001786720 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 2, 2021 | Class A Common Stock | MOption exerciseAcquired | +5,208 | $5.04 | +$26,248.32 | 897,344 | Direct | |
| Nov 2, 2021 | Class A Common Stock | MOption exerciseAcquired | +3,037 | $11.48 | +$34,864.76 | 900,381 | Direct | |
| Nov 2, 2021 | Class A Common Stock | SSaleDisposed | −3,241 | $160.26F2 | −$519,402.66 | 897,140 | Direct | |
| Nov 2, 2021 | Class A Common Stock | SSaleDisposed | −5,946 | $161.06F3 | −$957,662.76 | 891,194 | Direct | |
| Nov 2, 2021 | Class A Common Stock | SSaleDisposed | −5,613 | $161.94F4 | −$908,969.22 | 885,581 | Direct | |
| Nov 2, 2021 | Class A Common Stock | SSaleDisposed | −200 | $163.14 | −$32,628 | 885,381 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 2, 2021 | Class A Common Stock | MOption exerciseDisposed | −5,208 | $0.00 | $0 | 58,532 | Direct | |
| Nov 2, 2021 | Class A Common Stock | MOption exerciseDisposed | −3,037 | $0.00 | $0 | 51,633 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
This transaction was executed in multiple trades at prices ranging from $159.60 to $160.59. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.
- F3
This transaction was executed in multiple trades at prices ranging from $160.60 to $161.59. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.
- F4
This transaction was executed in multiple trades at prices ranging from $161.63 to $162.53. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.